Affimed (NASDAQ:AFMD) Given Average Rating of "Buy" by Brokerages

Affimed (NASDAQ:AFMD - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are presently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have covered the stock in the last year is $45.00.

Several research firms have weighed in on AFMD. HC Wainwright raised their price target on Affimed to $10.00 and gave the stock a "buy" rating in a research report on Monday, April 1st. Wells Fargo & Company dropped their price target on Affimed from $30.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, April 1st. StockNews.com began coverage on Affimed in a research report on Tuesday, January 2nd. They set a "sell" rating for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Affimed in a research report on Monday, April 1st.

Institutional Investors Weigh In On Affimed

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in shares of Affimed in the first quarter valued at $27,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Affimed in the second quarter valued at $31,000. UBS Group AG boosted its holdings in Affimed by 42.2% in the first quarter. UBS Group AG now owns 47,073 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 13,979 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Affimed by 30.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 3,202 shares during the last quarter. Finally, Advisor Group Holdings Inc. boosted its holdings in Affimed by 258.3% in the first quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company's stock valued at $40,000 after acquiring an additional 6,464 shares during the last quarter. Hedge funds and other institutional investors own 30.82% of the company's stock.

Affimed Price Performance

NASDAQ AFMD traded up $0.08 during mid-day trading on Thursday, hitting $5.91. The stock had a trading volume of 115,344 shares, compared to its average volume of 100,500. Affimed has a 52-week low of $2.23 and a 52-week high of $11.10. The company has a market cap of $89.99 million, a price-to-earnings ratio of -0.70 and a beta of 2.05. The company has a 50 day simple moving average of $5.55 and a 200 day simple moving average of $4.98. The company has a quick ratio of 3.23, a current ratio of 3.25 and a debt-to-equity ratio of 0.11.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.